New research links PSA and PSA density to long-term prostate cancer risk, supporting risk-adapted screening strategies. Learn more about the 20-year findings.

Many men with low levels could be spared from invasive procedures and frequent testing ...

Francis Medical, Inc., a privately-held medical device company, announced the first commercial procedure using the Vanquish Water Vapor Ablation System at Pinnacle Surgery Center in Austin, Texas, by ...

What key experiences or clinical gaps motivated your focus on advancing prostate cancer diagnostics, particularly MRI-led ...

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies' registrational ...

ORLANDO, Fla. (Ivanhoe Newswire) — The American Cancer Society reports that about one in eight men will be diagnosed with prostate cancer in their lifetime. The average age of men who get diagnosed is ...

A clinical trial at BC Cancer Victoria using artificial intelligence (AI) is reducing the number of radiation treatments to ...

Francis Medical today announced the first commercial procedure using its Vanquish water vapor ablation system.

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

Oxybutynin, a common drug to manage overactive bladder, may help alleviate hot flash symptoms among men receiving androgen deprivation therapy for prostate cancer.